The accelerated arrival of novel vaccines and immunotherapies into the clinical space spurred the emergence of fields like personalized medicine, immune profiling and immuno-monitoring built around increasingly sophisticated testing platforms. Among them, immunoassays in the ELISpot (Enzyme-Linked ImmunoSpot) family are the most frequently used functional assays for single-cell analysis. A relatively recent addition in the clinical testing space is that of multiplexed FluoroSpot assays, which enable simultaneous measurement of different analytes.
Traditional challenges of colorimetric ELISpot assays are, to some extent, magnified during the validation of multiplex FluoroSpot assays and routine sample testing. The new multidimensionality of the data is also a factor to consider. The innovative take on the field at Covance’s Vaccine and Novel Immunotherapeutic Laboratory will be presented and discussed during this presentation.
Rolando Pajon, PhD, Lead Scientist, Vaccine and Novel Immunotherapeutics, Covance
Rolando Pajon, PhD, has more than 20 years of experience leading multidisciplinary teams in research, development and evaluation of vaccines and immunotherapeutics. Dr. Pajon has over 35 peer-reviewed publications in the vaccine/immunology area, past WHO expert experience in quality control of meningococcal OMV vaccines, and more than 14 patent applications. Since 2015, Rolando leads the Covance Vaccine and Novel Immunotherapies Laboratory. He and his team represent Covance’s reach at providing strategic technical leadership in developing scientific approaches to clients and sponsors on a global scale.Message Presenter
Who Should Attend?
Chief Medical Officers, Chief Scientific Officers, plus senior level professionals from:
- Vaccine Developers
- Big Pharma
- Diagnostic Laboratories
- Immune Profiling Laboratories
Involved in the following fields:
- Personal Medicine
- Translational Medicine
- Immunotherapies OR Immunotherapy
What You Will Learn
- A review of the testing platforms for novel vaccines and immunotherapies
- Why ELISpot assays are the most frequently used functional assays for single-cell analysis
- Challenges in the validation of multiplex FluoroSpot assays and routine sample testing
Covance Inc., the drug development business of Laboratory Corporation of America Holdings (LabCorp) headquartered in Princeton, New Jersey, USA, is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®.
Our unique perspectives, built from decades of scientific expertise and precision delivery of the largest volume of drug development data in the world, helps our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Information on Covance’s solutions can be obtained through its website at www.covance.com.